Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ: PRAX) has granted restricted stock unit (RSU) awards to five new non-executive employees under its 2024 Inducement Plan. The awards cover a total of 3,688 shares of common stock and were approved by the Compensation Committee on May 1, 2025. The RSUs will vest over four years in equal annual installments, contingent on continued employment.
The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4). Praxis, a clinical-stage biopharmaceutical company, focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX) ha assegnato unità di azioni vincolate (RSU) a cinque nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivazione 2024. Le assegnazioni coprono un totale di 3.688 azioni ordinarie e sono state approvate dal Comitato per la Remunerazione il 1º maggio 2025. Le RSU matureranno in quattro anni con rate annuali uguali, a condizione che il rapporto di lavoro continui.
Le assegnazioni sono state effettuate come incentivi all'assunzione conformemente alla Regola di quotazione Nasdaq 5635(c)(4). Praxis, una società biofarmaceutica in fase clinica, si concentra sullo sviluppo di terapie per disturbi del sistema nervoso centrale caratterizzati da uno squilibrio tra eccitazione e inibizione neuronale.
Praxis Precision Medicines (NASDAQ: PRAX) ha otorgado unidades de acciones restringidas (RSU) a cinco nuevos empleados no ejecutivos bajo su Plan de Incentivos 2024. Las concesiones cubren un total de 3,688 acciones ordinarias y fueron aprobadas por el Comité de Compensación el 1 de mayo de 2025. Las RSU se consolidarán durante cuatro años en cuotas anuales iguales, condicionadas a la continuidad laboral.
Las concesiones se realizaron como incentivos de contratación conforme a la Regla de Listado Nasdaq 5635(c)(4). Praxis, una empresa biofarmacéutica en etapa clínica, se enfoca en desarrollar terapias para trastornos del sistema nervioso central caracterizados por un desequilibrio en la excitación-inhibición neuronal.
Praxis Precision Medicines (NASDAQ: PRAX)는 2024년 유인 계획에 따라 다섯 명의 신규 비임원 직원에게 제한 주식 단위(RSU)를 부여했습니다. 이 부여는 총 3,688주의 보통주를 포함하며, 2025년 5월 1일 보상위원회의 승인을 받았습니다. RSU는 계속 고용을 조건으로 4년에 걸쳐 연간 동일한 비율로 취득됩니다.
이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 고용 유인책으로 이루어졌습니다. 임상 단계의 생명공학 회사인 Praxis는 신경 세포의 흥분-억제 불균형이 특징인 중추신경계 장애 치료제 개발에 주력하고 있습니다.
Praxis Precision Medicines (NASDAQ : PRAX) a attribué des unités d'actions restreintes (RSU) à cinq nouveaux employés non cadres dans le cadre de son plan d'incitation 2024. Les attributions couvrent un total de 3 688 actions ordinaires et ont été approuvées par le comité de rémunération le 1er mai 2025. Les RSU seront acquises sur quatre ans par versements annuels égaux, sous réserve de la poursuite de l'emploi.
Ces attributions ont été faites en tant qu'incitations à l'embauche conformément à la règle de cotation Nasdaq 5635(c)(4). Praxis, une société biopharmaceutique en phase clinique, se concentre sur le développement de thérapies pour les troubles du système nerveux central caractérisés par un déséquilibre entre excitation et inhibition neuronale.
Praxis Precision Medicines (NASDAQ: PRAX) hat fünf neuen nicht-exekutiven Mitarbeitern im Rahmen seines Anreizplans 2024 Restricted Stock Units (RSUs) gewährt. Die Auszeichnungen umfassen insgesamt 3.688 Aktien des Stammkapitals und wurden am 1. Mai 2025 vom Vergütungsausschuss genehmigt. Die RSUs werden über vier Jahre in gleichen jährlichen Raten unverfallbar, vorausgesetzt, das Arbeitsverhältnis besteht weiterhin.
Die Gewährung erfolgte als Einstellungsanreiz gemäß Nasdaq-Listing-Regel 5635(c)(4). Praxis, ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, konzentriert sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems, die durch ein Ungleichgewicht zwischen neuronaler Erregung und Hemmung gekennzeichnet sind.
- None.
- None.
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to each employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
What is the vesting schedule for PRAX's May 2025 RSU grants?
How many shares were granted in Praxis Precision Medicines' May 2025 inducement awards?
What is the purpose of PRAX's 2024 Inducement Plan?
What type of company is Praxis Precision Medicines (PRAX)?
